About the company
Adduct Analys AB was founded in 2004 to commercialize technology developed at the Department of Environmental Chemistry at Stockholm University, Sweden. The company's main focus is to commercialize its unique and propriatary product series called TailorDose®. TailorDose® is a product line that meets the need for personalized cancer medicine relating to drugs that are difficult to dose, such as cyclophosphamide (CPA). The first product in this series is TailorDose®-CPA and is intended for cancer care in conditions such as breast cancer. There is a great medical need for personalized dosing of CPA. Our own clinical pilot study showed that over 35% of those treated with CPA received the wrong dose, and therefore did not get proper treatment. TailorDose® offers a solution for this problem. A single blood sample, followed by a quick analysis enables the physician to dose CPA correctly for each patient.
22nd of June. The collaboration with Aprea continues to the next level after reporting promising preliminary results.
1st of March 2016, a lab has been prepared in Biovation Park equipped e.g with a LC-MS instrument
1st of February 2016. Roland Stenutz, PhD, is employed as a full time researcher.
1st of January 2016. Adduct Analys signs a contract with Aprea, a medical company who develops the drug APR-246.
8 September 2015: Adduct Analys presents at Nordic Life Science Days in Stockholm, Sweden.
1 June 2015 Achim Orzechowski, PhD is appointed as CEO for the Company.
16 April 2015. Per Rydberg, Founder&CEO, presents at the Karolinska Institute Science Park Day in Solna, Sweden.
13 April 2015, Adduct Analys will move to new premises in the Biovation Park in Södertälje, Sweden.
5 Mars 2015, Adduct Analys appoints Achim Orzechowski, PhD as COO for the company.
February 2015, Lars Andåker is appointed as Chairman of the Board for Adduct Analys AB.
December 2014, Vinnova grants 2 MSEK to Adduct Analys for the product development of TailorDose™.
September 2014, TailorDose™ is suported with 0.5 MSEK from Vinnova (VINN Verification).
November 2013, Breast Cancer Foundation grants 0.4 MSEK to Adduct Analys.
March 2013, Adduct Analys recieves a major grant (3MSEK) from the Swedish Childhood Cancer Foundation .
January 2013: Korean TV portrays UppsalaBio and its activities to develop SMEs within biotechnology, TailorDose is exemplified.